A detailed history of Cfm Wealth Partners LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Cfm Wealth Partners LLC holds 4,049 shares of EXAS stock, worth $280,231. This represents 0.06% of its overall portfolio holdings.

Number of Shares
4,049
Holding current value
$280,231
% of portfolio
0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$42.43 - $70.83 $171,799 - $286,790
4,049 New
4,049 $275,000
Q1 2024

Apr 15, 2024

SELL
$56.27 - $73.77 $406,156 - $532,471
-7,218 Reduced 64.06%
4,049 $279,000
Q4 2023

Jan 11, 2024

SELL
$59.06 - $75.72 $10,394 - $13,326
-176 Reduced 1.54%
11,267 $833,000
Q1 2023

Apr 12, 2023

BUY
$47.19 - $70.77 $539,995 - $809,821
11,443 New
11,443 $775,000
Q3 2022

Oct 17, 2022

BUY
$31.97 - $49.37 $12,564 - $19,402
393 Added 3.56%
11,443 $372,000
Q1 2022

Apr 14, 2022

SELL
$57.56 - $82.54 $6,158 - $8,831
-107 Reduced 0.96%
11,050 $773,000
Q4 2021

Jan 21, 2022

BUY
$72.5 - $100.68 $41,035 - $56,984
566 Added 5.34%
11,157 $910,000
Q3 2021

Oct 25, 2021

BUY
$90.24 - $124.05 $101,520 - $139,556
1,125 Added 11.88%
10,591 $1.01 Million
Q2 2021

Jul 21, 2021

BUY
$93.66 - $139.27 $13,487 - $20,054
144 Added 1.54%
9,466 $1.18 Million
Q4 2020

Feb 10, 2021

BUY
$99.61 - $142.12 $80,484 - $114,832
808 Added 9.49%
9,322 $1.24 Million
Q3 2020

Nov 10, 2020

BUY
$72.92 - $102.01 $128,120 - $179,231
1,757 Added 26.0%
8,514 $868,000
Q2 2020

Aug 14, 2020

BUY
$55.75 - $92.75 $26,091 - $43,407
468 Added 7.44%
6,757 $587,000
Q1 2020

May 12, 2020

BUY
$37.9 - $104.44 $187,567 - $516,873
4,949 Added 369.33%
6,289 $365,000
Q4 2019

Jan 30, 2020

BUY
$77.66 - $99.74 $104,064 - $133,651
1,340 New
1,340 $120,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $12.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Cfm Wealth Partners LLC Portfolio

Follow Cfm Wealth Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cfm Wealth Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cfm Wealth Partners LLC with notifications on news.